These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 30256271)

  • 1. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM
    Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint Inhibitor-Induced Hemorrhagic Gastritis with Pembrolizumab.
    Rao BB; Robertson S; Philpott J
    Am J Gastroenterol; 2019 Feb; 114(2):196. PubMed ID: 30353060
    [No Abstract]   [Full Text] [Related]  

  • 3. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
    Woodbeck R; Metelitsa AI; Naert KA
    Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma.
    Sepúlveda M; Martinez-Hernandez E; Gaba L; Victoria I; Sola-Valls N; Falgàs N; Casanova-Molla J; Graus F
    Muscle Nerve; 2017 Dec; 56(6):E162-E167. PubMed ID: 28439919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Auto-immune gastritis induced by pembrolizumab, an anti-PD-1, in a melanoma patient.
    Vandepapelière J; Siplet J; Libbrecht L; Dano H; Baurain JF; Moreels T
    Acta Gastroenterol Belg; 2020; 83(3):482-484. PubMed ID: 33094598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
    Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
    Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
    Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
    J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K; McGettigan S; Elenitsas R; Chu EY
    J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
    Parakh S; Nguyen R; Opie JM; Andrews MC
    Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.
    Nardin C; Borot S; Beaudoin MA; Cattin F; Puzenat E; Gauthier AS; Schillo F; Borg C; Aubin F
    Invest New Drugs; 2019 Apr; 37(2):375-377. PubMed ID: 30145624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
    Blakeway EA; Elshimy N; Muinonen-Martin A; Marples M; Mathew B; Mitra A
    Melanoma Res; 2019 Jun; 29(3):338-341. PubMed ID: 30762712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.
    Kluger HM; Chiang V; Mahajan A; Zito CR; Sznol M; Tran T; Weiss SA; Cohen JV; Yu J; Hegde U; Perrotti E; Anderson G; Ralabate A; Kluger Y; Wei W; Goldberg SB; Jilaveanu LB
    J Clin Oncol; 2019 Jan; 37(1):52-60. PubMed ID: 30407895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 inhibitor induced alopecia areata.
    Guidry J; Brown M; Medina T
    Dermatol Online J; 2018 Dec; 24(12):. PubMed ID: 30677804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypothyroid ataxia complicating monoclonal antibody therapy.
    Badran A; Moran C; Coles AJ
    Pract Neurol; 2017 Dec; 17(6):482-484. PubMed ID: 28778931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-PD1-induced collagenous colitis in a melanoma patient.
    Baroudjian B; Lourenco N; Pagès C; Chami I; Maillet M; Bertheau P; Bagot M; Gornet JM; Lebbé C; Allez M
    Melanoma Res; 2016 Jun; 26(3):308-11. PubMed ID: 26990271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
    Earl DE; Loochtan AI; Bedlack RS
    Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
    Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
    JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
    Chiarion Sileni V; Mandalà M; Queirolo P
    Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
    Arianayagam S; Ieremia E; Matin RN
    Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
    [No Abstract]   [Full Text] [Related]  

  • 20. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
    Ivashko IN; Kolesar JM
    Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.